




SEC Info - GL Partners Capital Management Ltd, et al. - ‘SC 13D’ on 11/19/12 re: Sciclone Pharmaceuticals Inc - Filing Submission










SEC Info uses JavaScript!  To view pages properly, enable JavaScript in your browser.


    SEC Info      Home      Search      My Interests      Help      Sign In      Please Sign In




GL Partners Capital Management Ltd, et al. – ‘SC 13D’ on 11/19/12 re: Sciclone Pharmaceuticals IncOn:  Monday, 11/19/12, at 1:45pm ET   ·   Accession #:  1410578-12-118   ·   File #:  5-43408
Previous ‘SC 13D’:  None   ·   Next:  ‘SC 13D/A’ on 11/21/13   ·   Latest:  ‘SC 13D/A’ on 6/8/17



  in 
this entire Filing.
an "Entity" Search.
  Show 
Docs searched
 and 
every "hit".
the 1st "hit".

Help... Wildcards:  ? (any letter),  * (many).  Logic:  for Docs:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).    ↓Bottom
 
T-->  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/19/12  GL Partners Capital Mgmt Ltd      SC 13D                 2:237K Sciclone Pharmaceuticals Inc      Merrill Corp FA/JMSii/FA
          GL Capital Management GP L.P.
          GL Capital Management GP Ltd
          GL China Opportunities Fund L.P.
          GL Trade Investment Ltd
          Zhenfu LiF-->General Statement of Beneficial Ownership   —   Schedule 13DFiling Table of Contents
Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D      General Statement of Beneficial Ownership           HTML    142K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     13K 

_-->Filing Submission 0001410578-12-000118 – SGML TextRaw SGML-Tagged Text that was Submitted by:  Merrill Corp FA/JMSii/FA  (as Filing Agent)Show all <DOCUMENT> <TEXT> elements below                  ↑Top ↓Bottom 
<SUBMISSION>                                                                    
<ACCEPTANCE-DATETIME>		20121119134545
<ACCESSION-NUMBER>		0001410578-12-000118
<TYPE>				SC 13D
<PUBLIC-DOCUMENT-COUNT>		2
<FILING-DATE>			20121119
<DATE-OF-FILING-DATE-CHANGE>	20121119
<GROUP-MEMBERS>			GL CAPITAL MANAGEMENT GP L.P.
<GROUP-MEMBERS>			GL CAPITAL MANAGEMENT GP LTD
<GROUP-MEMBERS>			GL CHINA OPPORTUNITIES FUND L.P.
<GROUP-MEMBERS>			GL TRADE INVESTMENT LTD
<GROUP-MEMBERS>			ZHENFU LI
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>		SCICLONE PHARMACEUTICALS INC
<CIK>				0000880771
<ASSIGNED-SIC>			2834
<IRS-NUMBER>			943116852
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>			SC 13D
<ACT>				34
<FILE-NUMBER>			005-43408
<FILM-NUMBER>			121214052
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			950 TOWER LANE
<STREET2>			SUITE 900
<CITY>				FOSTER CITY
<STATE>				CA
<ZIP>				94404-2125
<PHONE>				650-358-3456
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			950 TOWER LANE
<STREET2>			SUITE 900
<CITY>				FOSTER CITY
<STATE>				CA
<ZIP>				94404-2125
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>		GL Partners Capital Management Ltd
<CIK>				0001562291
<IRS-NUMBER>			000000000
<STATE-OF-INCORPORATION>	E9:  This is an SEC-specific code that maps to 
				Cayman Islands [ U.K. ] {KY}
<FISCAL-YEAR-END>		1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>			SC 13D
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			A-31F,GLOBAL TRADE,MANSION 9,GUANGHUA RD
<CITY>				BEIJING
<STATE>				F4:  This is an SEC-specific code that maps to 
				China {CN}
<ZIP>				100020
<PHONE>				86-010-5961 1212
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			A-31F,GLOBAL TRADE,MANSION 9,GUANGHUA RD
<CITY>				BEIJING
<STATE>				F4:  This is an SEC-specific code that maps to 
				China {CN}
<ZIP>				100020
</MAIL-ADDRESS>
</FILED-BY>
</SUBMISSION>↑Top
Filing Submission 0001410578-12-000118   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2017 Fran Finnegan & Company.  All Rights Reserved.About – Privacy – Redactions – Help —
Fri, 28 Jul 22:09:42.0 GMT 



GL PARTNERS CAPITAL MANAGEMENT LTD Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      GL PARTNERS CAPITAL MANAGEMENT LTD
                    

•   BEIJING, F4
                      
How do I update this listing?




                                             GL Partners Capital Management LTD is based out of Beijing.    WhaleWisdom has at least 11 13D/G filings in our database for GL Partners Capital Management LTD.
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from GL PARTNERS CAPITAL MANAGEMENT LTD, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




gl partners capital management ltd


A-31F,GLOBAL TRADE,MANSION 9,GUANGHUA RD

BEIJING
F4
                                                        
                                                    100020


              Business Phone:
              86-010-5961 1212







Recent SEC Filings




SC 13D/A filed on 06/08/2017
SC 13D/A filed on 02/17/2017
SC 13D/A filed on 11/14/2016
3 filed on 02/26/2016
SC 13D/A filed on 02/22/2016
SC 13D/A filed on 02/09/2016
SC 13D/A filed on 08/21/2015
SC 13D/A filed on 08/17/2015
SC 13G/A filed on 02/13/2014
SC 13G filed on 11/21/2013











Current 13D/G Holdings


Stock
Sector
Shares Held
Market Value
Rank
Source
Source Date





ScicCone Pharmaceuticals Inc. (SCLN)


      HEALTH CARE
    

      4,750,116
    

      47,976,171.60
    

      1
    

      13D
    

      2017-06-07
    



China Biologic Products Inc (CBPO)


      HEALTH CARE
    

      1,619,777
    

      46,730,566.45
    

      2
    

      13G
    

      2013-12-31
    











Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free



















GL Partners Capital Management Ltd, BizPedia.xyz - We monitor changes in companies





















BizPedia.xyz  - We monitor changes in companies
 






GL Partners Capital Management Ltd


FREE EMAIL WATCHDOG
Get free email notifications about news in GL Partners Capital Management Ltd.










The service is free and you can unsubscribe at any time.

General | Filings (12)
CIK Number: 0001562291

GL Partners Capital Management Ltd addressA-31F,GLOBAL TRADE,MANSION 9,GUANGHUA RDBEIJING 100020
Earliest known filing
November 2012
Latest known filing
June 2017




Company filings
SEC filings are a great source of information for companies including investments, company events, and all sorts of other information. 
GL Partners Capital Management Ltd has 12 filings. View GL Partners Capital Management Ltd filings.
Similar companiesGLOBAL INNOVATIVE INVESTMENT GROUP Ltd, Global Transport Income Fund Master Partnership SCSp, GlobeKick LLC, Global Frontier Life Sciences Opportunity Fund I, L.P., Global Bridge Capital USD Fund I, L.P., GLSEQ, LLC, GLOBALFOUNDRIES Inc., Glance Networks, Inc., Glass-Gannett SPV, LLC, Glynn Partners V, L.P., Globalflyte, Inc., Glendon Opportunities Fund II, L.P., Global Renewable Power Fund II (D), L.P., Global Liquid Markets, LLC, Glenrose Avenue Investors, LLC, Glassman Andrew L, GlamST, Global Financial Private Capital, LLC, GLOBAL EDUCATION WITHOUT LIMITS, LLC, Global Equity Absolute Return Investors (Cayman), Ltd., Global Wealth Investments, Inc., Glickman Matthew, Global Indy I, LLC, GLADE BROOK PRIVATE INVESTORS X LLC, Glenobey Prospect Partners, Global Alpha International Small Cap Fund LP, Global Return Value Investments, LP, GlobeChat, Inc., Glovista US Feeder Fund LP, GLOBAL SYNERGY HOLDINGS, INC., Glowb Lights LLC, Global Allocation Fund, GLORIETTA MANAGEMENT GROUP, INC., Global SC Finance III Ltd, Glimpse K12, Inc., Global Data Solutions Ltd, Glean Tech Fund LP, Glenmede Private Investment Fund X, L.L.C., GL Chapel Hill Fund LLC, Glen Harbor Capital Management LLC, GLN Holdings, Inc, GlassBridge Quant Strategy Onshore, LP, GlassBridge Quant Strategy Offshore, Ltd., GLCA Holdco II, LLC, GLCA Holdco, LLC, Glass Financial, Inc., Global Infrastructure Solutions Inc., Global Private Alpha, LP, GLL Health Sciences Fund Ltd, Global Bridge Capital, Inc.














BizPedia.xyz collect news, financial information, SEC filings, stock information, contact information, personal information, information about investments, etc. about GL Partners Capital Management Ltd. 







GL Partners Capital Management Ltd - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











GL Partners Capital Management Ltd
Check out list of companies and businesses related to GL Partners Capital Management Ltd. Find out GL Partners Capital Management Ltd address and contact details. View other people related to GL Partners Capital Management Ltd - coworkers, colleagues, companions, etc.
Address:   

UNIT 3001, CHINA WORLD TOWER 2, NO. 1 JIAN GUO MEN WAI AVENUE BEIJING 100004 China




Companies related to GL Partners Capital Management Ltd
CIKCompany NamePositionCompany Address0000880771SCICLONE PHARMACEUTICALS INC950 TOWER LANE SUITE 900 FOSTER CITY 94404-2125




GL Partners Capital Management Ltd on the Web
Persons related to GL Partners Capital Management Ltd - SCICLONE PHARMACEUTICALS INCNamePositionCityABG Management LtdHONG KONGAlly Bridge LB Healthcare Master Fund LtdHONG KONGAlly Bridge LB Management LtdHONG KONGS P A  APTAFINROMEPeter  BarrettDirector CAMBRIDGEPeter  BarrettDirector FOSTER CITYPeter  BarrettDirector FOSTER CITYJOHN D  BAXTERJOHN D  BAXTERDirector SAN MATEOJOHN D  BAXTERDirector FOSTER CITYFriedhelm  BlobelPresident & CEO SAN MATEOFriedhelm  BlobelPresident & CEO FOSTER CITYFriedhelm  BlobelPresident & CEO FOSTER CITYEDWIN C  CADMANEDWIN C  CADMANDirector SAN MATEORoberto  CameriniDirector POMEZIA (ROME)Roberto  CameriniDirector FOSTER CITYRoberto  CameriniDirector FOSTER CITYCLAUDIO  CAVAZZA10% Owner ROMECLAUDIO  CAVAZZA10% Owner ROME ITALYCLAUDIO  CAVAZZA10% Owner ROMECLAUDIO  CAVAZZA10% Owner ROMEPAOLO  CAVAZZA10% Owner LUGANOPAOLO  CAVAZZA10% Owner LUGANOPAOLO  CAVAZZALUGANOPAOLO  CAVAZZA10% Owner LUGANOPAOLO  CAVAZZA10% Owner LUGANO, SWITZERLANDPAOLO  CAVAZZA10% Owner LUGANOPAOLO  CAVAZZA10% Owner LAGANONANCY T  CHANGDirector HOUSTONNANCY T  CHANGDirector FOSTER CITYNANCY T  CHANGDirector FOSTER CITYChaumiere Consultadoria & Servicos SDC Unipessoal LDA FUNCHAL - MADEIRACarey  ChernGeneral Counsel FOSTER CITYWilson Wai-Shun  CheungCFO & Senior VP, Finance FREMONTWilson Wai-Shun  CheungCFO & Senior VP, Finance FOSTER CITYFARMACEUTICA LDA  DEFIANTEFUNCHAL MADEIRAFARMACEUTICA LDA  DEFIANTEMADEIRAFARMACEUTICA LDA  DEFIANTEMADEIRADragon Alpha LPBEIJINGGL CAPITAL MANAGEMENT GP LtdBEIJINGJERE E  GOYANJERE E  GOYANDirector SAN MATEOJie Jackie  GuanFOSTER CITYRichard J  HawkinsDirector SAN MATEORichard J  HawkinsDirector FOSTER CITYRichard J  HawkinsDirector FOSTER CITYRichard J  HawkinsDirector FOSTER CITYROLF H  HENELROLF H  HENELDirector SAN MATEOROLF H  HENELDirector FOSTER CITYROLF H  HENELDirector FOSTER CITYIVAN  HUIPrincipal Accounting Officer SAN MATEOIVAN  HUIPrincipal Accounting Officer FOSTER CITYJade Park Investments LtdBEIJINGTrevor M  JonesDirector REIGATE SURREYTrevor M  JonesDirector FOSTER CITYRobert  KingSVP of Prod. Dev/Supply Chain FOSTER CITYANTHONY GREGG  LAPOINTEDirector FOSTER CITYANTHONY GREGG  LAPOINTEDirector GAITHERSBURGANTHONY GREGG  LAPOINTEDirector FOSTER CITYGregg Anthony  LapointeDirector UNION CITYGregg Anthony  LapointeDirector GAITHERSBURGIra D  LawrenceDirector SAN MATEOIra D  LawrenceDirector FOSTER CITYIra D  LawrenceDirector FOSTER CITYBin  LiHONG KONGSimon  LiDirector FOSTER CITYLanchu  LiuBEIJINGMark  LotterSHANGHAIMark  LotterCEO, China Operations SHANGHAIMark  LotterCEO, China Operations FOSTER CITYRaymond Anthony  LowVP, Finance & Controller FREMONTRaymond Anthony  LowVP, Finance & Controller FOSTER CITYChuncai  MengGen. Counsel & VP Compliance SHANGHAIChuncai  MengGen. Counsel & VP Compliance FOSTER CITYIsrael  RiosSr. VP, Medical Affairs & CMO FOSTER CITYIsrael  RiosChief Medical Officer FOSTER CITYIsrael  RiosChief Medical Officer FOSTER CITYALFRED R  RUDOLPHChief Operating Officer SAN MATEOJON S  SAXEDirector JON S  SAXEDirector FOSTER CITYJON S  SAXEDirector FOSTER CITYJON S  SAXEDirector SAN MATEOHANS P  SCHMIDPres & Mng Dir, SciClone Int'l SAN MATEOHANS P  SCHMIDPres & Mng Dir, SciClone Int'l FOSTER CITYHANS P  SCHMIDPres & Mng Dir, SciClone Int'l FOSTER CITYHANS P  SCHMIDPres & Mng Dir, SciClone Int'l FOSTER CITYDONALD R  SELLERSPresident and CEO SAN MATEOTAU FINANZIARIA SPA  SIGMA10% Owner ROME ITALYTAU FINANZIARIA SPA  SIGMA10% Owner ROMETAU FINANZIARIA SPA  SIGMA10% Owner RINETAU FINANZIARIA SPA  SIGMA10% Owner ROMETAU FINANZIARIA SPA  SIGMA10% Owner ROMES.A.  SinafGary  TitusSenior VP Finance & CFO FOSTER CITYGary  TitusSenior VP Finance & CFO FOSTER CITYGary  TitusCFO & Sr. VP Finance FOSTER CITYWinnie Wing-Kei  TsoFOSTER CITYRICHARD A  WALDRONEVP & CFO SAN MATEOStephanie  WongVP, Finance and Controller FOSTER CITYDEAN S  WOODMANDEAN S  WOODMANDirector SAN MATEODEAN S  WOODMANDirector SAN MATEODEAN S  WOODMANDirector FOSTER CITYDEAN S  WOODMANDirector FOSTER CITYLan  XieVP Finance, China CFO FOSTER CITYLan  XieVP Finance, China CFO FOSTER CITYMin  YinVP Compliance & Internal Audit FOSTER CITYFan  YuHONG KONGHong  ZhaoCEO, China Operations SHANGHAI,Hong  ZhaoCEO, China Operations FOSTER CITY












 






        13D Filing: Gl Partners Capital Management Ltd and Sciclone Pharmaceuticals Inc (SCLN) - Insider Monkey                                     
        Companies 0 See All     Hedge Funds 0 See All    Insiders 0 See All    Institutional Investors 0 See All   Click here to see all  results for  Sorry, no results has been found matching your query.                   Adblocker Detected    Dear Valued Visitor, We have noticed that you are using an ad blocker software.
    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. To view this article, you can disable your ad blocker and refresh this page or simply login. We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.    
   Hedge Funds  13D Filing: Gl Partners Capital Management Ltd and Sciclone Pharmaceuticals Inc (SCLN)    Published on June 9, 2017 at 1:06 pm by  
                                Insider Monkey Staff
                                  in Hedge Funds         Page 1 of 11Next &gt&gt          You can access the original SEC filing by clicking here. Ownership Summary Table   Name   Sole Voting Power   Shared Voting Power   Sole Dispositive Power   Shared Dispositive Power   Aggregate Amount Owned Power   Percent of Class    GL Trade Investment Limited   4,750,116   0   4,750,116   0   4,750,116   9.2%  GL China Opportunities Fund   4,750,116   0   4,750,116   0   4,750,116   9.2%  GL Capital Management GP   4,750,116   0   4,750,116   0   4,750,116   9.2%  GL Capital Management GP Limited   4,750,116   0   4,750,116   0   4,750,116   9.2%  GL Partners Capital Management Limited   0   4,750,116   0   4,750,116   4,750,116   9.2%  Zhenfu Li   0   4,750,116   0   4,750,116   4,750,116   9.2%   Page 1 of 11 – SEC Filing    UNITED
STATES SECURITIES
AND EXCHANGE COMMISSION Washington,
D.C. 20549 Schedule
13D   Under the Securities Exchange Act of
1934(Amendment No. 8)* Information to be Included in Statements
Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a)     SCICLONE PHARMACEUTICALS, INC.   (Name of Issuer)       Common Stock, par value US$0.001 per share   (Title of Class of Securities)       80862K104   (CUSIP Number)        Ms. Shirley Lin   Unit 3001, China World Tower 2, No.1 Jian Guo Men Wai Avenue   Beijing 100004, People’s Republic of China   Phone: +86 10 5961-1212   (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)       June 7, 2017   (Date of Event Which Requires Filing of this Statement)    If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ¨ Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are
to be sent.    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.    The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).  Follow Sciclone Pharmaceuticals Inc (NASDAQ:SCLN)Follow Sciclone Pharmaceuticals Inc (NASDAQ:SCLN)       Trade (NASDAQ:SCLN) Now!        Page 1 of 11Next &gt&gt       Related Insider Monkey Articles13D Filing: Horton Capital Partners, LLC and Creative Realities Inc. (CREX)13D Filing: GAMCO Investors and Cavco Industries Inc (CVCO)13D Filing: Lone Star Value Management and Superior Drilling Products Inc. (...13D Filing: Red Mountain Capital and Air Transport Services Group Inc. (ATSG...13D Filing: Marcato Capital Management and Buffalo Wild Wings Inc (BWLD)13D Filing: Trian Partners and Wendy’s Co (WEN) (NASDAQ:SCLN) Gl Partners Capital Management Ltd SciClone Pharmaceuticals Inc. (SCLN) SEC 13D Filing                Insider Monkey Small Cap Strategy      Download a free copy of our newsletter and see the details inside!     Hedge Fund Resource Center    How to Beat the Market by 20 Percentage Points Why Track Hedge Funds? Download a Free Edition! Why You Should DUMP Your Hedge Funds 6 Things You Didn't Know About Hedge Funds      Billionaire Hedge Funds          Warren Buffett Berkshire Hathaway $147,985,198,000          David Einhorn Greenlight Capital $5,818,885,000          George Soros Soros Fund Management $4,321,285,000          T Boone Pickens BP Capital $318,631,000          Jim Simons Renaissance Technologies $63,208,016,000          Leon Cooperman Omega Advisors $2,269,539,000          Carl Icahn Icahn Capital LP $22,373,522,000          Steve Cohen Point72 Asset Management $14,303,015,000          John Paulson Paulson & Co $7,934,312,000          David Tepper Appaloosa Management LP $5,640,040,000           About Us Contact Us Terms Of Use Privacy Policy       Next Post

   Home Hedge Funds Markets Blog Authors About Us Contact Us Privacy Policy Terms of Use Site Map  All text and design is copyright ©2016 Koala Guide LLC. All rights reserved.            



﻿







Gl Partners Capital Management Ltd Bought Sciclone Pharmaceuticals Inc’s Shares – Octafinance





















































 








Friday, 28 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can’t Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Gl Partners Capital Management Ltd Bought Sciclone Pharmaceuticals Inc’s Shares


08/21/2015  by OctaStaff 
			in SEC 13G & 13D Filings 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Gl Partners Capital Management Ltd Bought Sciclone Pharmaceuticals Inc’s Shares and is was published by Octafinance.com at http://www.octafinance.com/gl-partners-capital-management-ltd-bought-sciclone-pharmaceuticals-incs-shares/170125/.CaptchaSubmitGl Partners Capital Management Ltd increased Position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
Gl Partners Capital Management Ltd has filled a SC 13D/A form regarding Sciclone Pharmaceuticals Inc  10.90 -0.05 -0.46%. Filing Link: 000114420415051156.  Per Gl Partners Capital Management Ltd’s filing, the filler reported increased stake in the company by 10.55% to 4,766,061 shares. Gl Partners Capital Management Ltd now owns 9.5% of the Health Care-company. This form was required due to trading activity on August 20, 2015.
Sciclone Pharmaceuticals Inc Hedge Funds Ownership

Latest SEC filings show 125 hedge funds and institutional investors own Sciclone Pharmaceuticals Inc. The institutional ownership of the company in Q1 2015 is high, at 65.81% of the shares outstanding. They decreased by 1429905 the total shares they hold. As of that quarter these institutional investors owned 33072006 shares. A total of 17 funds opened new positions in Sciclone Pharmaceuticals Inc and 51 increased their holdings. There were 16 funds that closed their positions and 34 that reduced them.
 Wilmot B. Harkey And Daniel Mack Nantahala Capital Management Llc is the most positive institutional investor on Sciclone Pharmaceuticals Inc, with ownership of 1522625 shares as of Q1 2015 for 2.25% of the fund’s portfolio.  Sensato Investors Llc is another positive player owning 1552482 shares of the company or 2.96% of their stocks portfolio. AL Rfg Advisory Group Llc have 0.16% of their stock portfolio invested in the stock for 24700. Further, Ativo Capital Management Llc disclosed it had purchased a stake worth 0.25% of the fund’s stock portfolio in the company. The TX Ranger Investment Management Lp was also a notable investor in the firm, owning 119540 shares. Sciclone Pharmaceuticals Inc is 0.05% of the fund’s stock portfolio.
Company Profile
SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin, therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc, a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex, a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications, and RapidFilm, an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Form 13D is SEC filing that must be submitted within 10 days, by anyone who acquires beneficial ownership of more than 5% of any publicly traded securities. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing. These filings may be a precursor to hostile takeovers, company breakups, and other “change of control” events.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.







 
Tagged: NASDAQ:SCLN



Shipbob I Fund A Series Of Wefunds  Filing. Michael Norman  Filed Aug 20  form PITTENGER & ANDERSON INC Just Filed Its Q2 2015 Stock Holdings 



 





Free Email Newsletter
    Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:







Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking CrisisAre US – Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?—put volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs’ Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?


























The Weekly Hub
		
		
		
		
		
		
		
 

 






































Trending
Business
Privacy Policy
Contact








Latest Headlines





Atlantica Yield PLC (ABY) Analysts See $0.11 EPS
Dolores Ford
Wall Street await Atlantica Yield PLC (NASDAQ:ABY) to release earnings on August, 4. Analysts forecast earnings per share of $0.11, up exactly $0.08 or 266.67 % from 2014’s $0.03 EPS. The expected ABY’s profit could reach $11.16M giving the stock 49.05 P/E in the case that $0.11 earnings per share is reported. ... 




Arbor Realty Trust Inc (ABR) EPS Estimated At $0.19
Zillow Group, Inc. (ZG) Analysts See $-0.14 EPS
$-0.53 EPS Expected for Zafgen Inc (ZFGN)
Olympic Steel, Inc. (ZEUS) Analysts See $0.42 EPS
Zendesk Inc (ZEN) Analysts See $-0.27 EPS




Zillow Group, Inc. (Z) EPS Estimated At $-0.17
Analysts See $0.61 EPS for Yum! Brands, Inc. (YUM)
YRC Worldwide Inc (YRCW) EPS Estimated At $0.48
YPF SA (ADR) (YPF) Analysts See $0.04 EPS
$8.24 EPS Expected for Alleghany Corporation (Y)




$-0.66 EPS Expected for Acceleron Pharma Inc (XLRN)
Wyndham Worldwide Corporation (WYN) Analysts See $1.50 EPS
EPS for The Western Union Company (WU) Expected At $0.42
Analysts See $0.50 EPS for Weight Watchers International, Inc. (WTW)
$0.03 EPS Expected for W&T Offshore, Inc. (WTI)






 





  Recent Posts 

Atlantica Yield PLC (ABY) Analysts See $0.11 EPS


Arbor Realty Trust Inc (ABR) EPS Estimated At $0.19


Zillow Group, Inc. (ZG) Analysts See $-0.14 EPS


$-0.53 EPS Expected for Zafgen Inc (ZFGN)


Olympic Steel, Inc. (ZEUS) Analysts See $0.42 EPS


Zendesk Inc (ZEN) Analysts See $-0.27 EPS


Zillow Group, Inc. (Z) EPS Estimated At $-0.17


Analysts See $0.61 EPS for Yum! Brands, Inc. (YUM)


YRC Worldwide Inc (YRCW) EPS Estimated At $0.48


YPF SA (ADR) (YPF) Analysts See $0.04 EPS























            	Get the Next Big Winner in your inbox Before the Bell







            
Lists*Consumer Eagle




Twitter Auto Publish Powered By : XYZScripts.com























New York State Teachers Retirement System Cuts Position in SciClone Pharmaceuticals, Inc. (SCLN) | Daily Political










































































Home
About/Contact
Columnists
Privacy Policy
























Headlines
Politics
Nation
World
Issues
Economy
Finance




















SciClone Pharmaceuticals Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. with our FREE daily email newsletter:



 






Follow DailyPolitical

 
 










Latest News



OFG Bancorp (NYSE:OFG) Position Maintained by New York State Teachers Retirement System					

New York State Teachers Retirement System Cuts Position in SciClone Pharmaceuticals, Inc. (SCLN)					

New York State Teachers Retirement System Sells 5,500 Shares of Avis Budget Group, Inc. (NASDAQ:CAR)					

New York State Teachers Retirement System Holds Stake in Nanometrics Incorporated (NASDAQ:NANO)					

Piper Jaffray Companies (PJC) Shares Bought by Renaissance Technologies LLC					

Renaissance Technologies LLC Sells 259,269 Shares of Big 5 Sporting Goods Corporation (NASDAQ:BGFV)					

Renaissance Technologies LLC Invests $7.34 Million in International Paper Company (IP)					

US Capital Advisors Comments on Gulfport Energy Corporation’s Q2 2017 Earnings (NASDAQ:GPOR)					

Mersana Therpts (NASDAQ:MRSN) Expected to Post Q2 2017 Earnings of ($0.58) Per Share					

Research Analysts Set Expectations for OGE Energy Corporation’s Q2 2017 Earnings (NYSE:OGE)					

Assa Abloy AB (OTCMKTS:ASAZY) Rating Increased to Buy at Zacks Investment Research					

Tmx Group Limited’s (TSE:X) Sector Perform Rating Reaffirmed at Scotiabank					

Jamieson Wellness Inc (JWEL) Earns Outperform Rating from CIBC					

PrairieSky Royalty Ltd (TSE:PSK) Given New C$31.00 Price Target at GMP Securities					

KCG Holdings Inc. Sells 4,523 Shares of American Financial Group, Inc. (AFG)					

KCG Holdings Inc. Cuts Position in Fortinet, Inc. (NASDAQ:FTNT)					

Amalgamated Bank Buys Shares of 4,464 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)					

United Capital Financial Advisers LLC Reduces Stake in PayPal Holdings, Inc. (PYPL)					

Santander Consumer USA Holdings Inc. (SC) Stake Increased by Amalgamated Bank					

Amalgamated Bank Has $193,000 Stake in Rambus, Inc. (NASDAQ:RMBS)					





 





						New York State Teachers Retirement System Cuts Position in SciClone Pharmaceuticals, Inc. (SCLN)					

						 July 28th, 2017  - 0 comments - Filed Under -
 by Trevor Kearing 


							Filed Under: Finance - SEC Filing Articles 







Tweet










New York State Teachers Retirement System lowered its position in shares of  SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 0.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor  owned 40,821 shares of the specialty pharmaceutical company’s stock after selling 100 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of SciClone Pharmaceuticals worth $400,000 as of its most recent SEC filing. 
Other hedge funds have also made changes to their positions in the company. LS Investment Advisors LLC boosted its stake in shares of  SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 8,355 shares in the last quarter.  BNP Paribas Arbitrage SA boosted its stake in shares of  SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,320 shares during the period.  Municipal Employees Retirement System of Michigan boosted its stake in shares of  SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 310 shares during the period.  Mason Street Advisors LLC boosted its stake in shares of  SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 881 shares during the period.  Finally, OppenheimerFunds Inc. boosted its stake in shares of  SciClone Pharmaceuticals by 29.9% in the first quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 3,065 shares during the period. 72.00% of the stock is owned by institutional investors and hedge funds. 
Shares of SciClone Pharmaceuticals, Inc. (SCLN) opened at 10.95 on Friday. The stock has a 50 day moving average of $10.92 and a 200-day moving average of $10.10. SciClone Pharmaceuticals, Inc. has a 52 week low of $8.55 and a 52 week high of $11.10. The stock has a market capitalization of $566.47 million, a PE ratio of 15.40 and a beta of 1.71. 
TRADEMARK VIOLATION NOTICE: This story was first  posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/07/28/new-york-state-teachers-retirement-system-cuts-position-in-sciclone-pharmaceuticals-inc-scln.html. 




Separately, Maxim Group  set a $14.00 price objective on shares of SciClone Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 11th.
In related news, CEO Friedhelm Blobel sold 35,044 shares of the business’s stock in a transaction on Friday, June 30th. The shares were sold at an average price of $11.00, for a total value of $385,484.00. Following the completion of the transaction, the chief executive officer now directly owns 149,863 shares in the company, valued at approximately $1,648,493. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the completion of the transaction, the chief financial officer now owns 14,372 shares of the company’s stock, valued at $154,499. The disclosure for this sale can be found here. Over the last quarter, insiders sold 253,726 shares of company stock valued at $2,662,024. Company insiders own  5.16% of the company’s stock. 
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.






Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 
















 Comment on this Post

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be placed in moderation!




Latest News




Jeff Sessions Spoke of Resigning After Tensions Increase with Trump





President Trump’s Tweets Complicate Already Complicated Week





World Leaders Very Critical of Paris Agreement Decision by Trump





Aide to President Trump Resigns With More Expected





Scud-Class Missile Launched by North Korea














			© DailyPolitical, LLC 2009-2017. All rights reserved. 


Privacy Policy |
			About | Columnists 
			| Contact 


































































GL Partners Capital Management Ltd - Sciclone Pharmaceuticals Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsGL Partners Capital Management LtdSciclone Pharmaceuticals (SCLN)Ten Percent Owner Not RankedGL Partners Capital Management Ltd's PerformanceGL Partners Capital Management Ltd has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Insider Holdings 100.0% Sciclone Pharmaceuticals (SCLN)$54MSee the Top Stocks by Insiders > Insider RolesSciclone Pharmaceuticals (SCLN): Ten Percent OwnerSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Sciclone Pharmaceuticals (SCLN)Transaction Type: Informative BuyDates: Feb 26, 2016 - Feb 26, 2017Gain: +0.0%See the Latest Stocks Traded by Insiders > GL Partners Capital Management Ltd's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateSCLNSciclone PharmaceuticalsTen Percent Owner$54,386,451Informative Buy(undisclosed)Feb 26, 2016GL Partners Capital Management Ltd has not reported any informative transactions for SCLN, therefore, performance cannot be measured. Track Record DateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Feb 26, 2016 Informative Buy (undisclosed) 4,750,116 $9.92 N/A See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by



























 SECGems: GL Partners Capital Management Ltd 







































  







			Data feeds now available
			Excel / CSV / Java / Python /etc 
Database
Learn more









  




  


  






























 GL Partners Capital Management Ltd 
		     










 Info




 Ownership




 Filings
12















←


 1 


→



 Filings:    (1 of 12 - Total: 12)









		
			June 8, 2017 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-17-031625.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Feb. 17, 2017 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-17-009705.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Nov. 14, 2016 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-16-133591.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Feb. 26, 2016 .
		
	


				Issuer
			

 
					SCICLONE PHARMACEUTICALS INC 
					

 
					SCLN
				


				Reporting Owner
			

 
					GL Partners Capital Management Ltd 
					


					[
					      10% owner,              
					
					
					
					
					
					]
				


 
					GL CAPITAL MANAGEMENT GP Ltd 
					


					[
					      10% owner,              
					
					
					
					
					
					]
				

Signed By

 GL Partners Capital Management Limited by  Li Zhenfu Director


 GL Capital Management GP Limited by  Li Zhenfu Director






		Preview. 
	

 
			View filing ...
		






				3
			




 
					0001144204-16-084414.nc
				

 
					XML (1) 
				





					Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 22, 2016 
			







Common Stock, par value $0.001 per share 


Total owned:
4,750,116 
 
 
  
 	[ See Footnote ] 
 
 
 
 
 

 














		
			Feb. 22, 2016 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-16-083617.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Feb. 9, 2016 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-16-079709.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Aug. 21, 2015 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-15-051156.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Aug. 17, 2015 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-15-050226.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Feb. 13, 2014 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 China Biologic Products, Inc. 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13G/A
			




 
					0001144204-14-008280.nc
				






					Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and institutions
				

















		
			Nov. 21, 2013 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D/A
			




 
					0001144204-13-063408.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				

















		
			Nov. 21, 2013 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 China Biologic Products, Inc. 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13G
			




 
					0001144204-13-063410.nc
				






					Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and institutions
				

















		
			Nov. 19, 2012 .
		
	

Filed By

 GL Partners Capital Management Ltd 

Subject Company

 SCICLONE PHARMACEUTICALS INC 

Group Member

 GL CAPITAL MANAGEMENT GP L.P.


 GL CAPITAL MANAGEMENT GP LTD


 GL CHINA OPPORTUNITIES FUND L.P.


 GL TRADE INVESTMENT LTD


 ZHENFU LI






		Preview. 
	

 
			View filing ...
		






				SC 13D
			




 
					0001410578-12-000118.nc
				






					Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
				














 





db
 
 








































